Clinical Trials Logo

Filter by:
NCT ID: NCT06149637 Recruiting - Thyroid Cancer Clinical Trials

Lateral Cervical Node Dissection in Differentiated Thyroid Cancer.

Start date: August 1, 2023
Phase: N/A
Study type: Interventional

The objective of this study is to compare shoulder and neck morbidity and the effectiveness of cervical lateral nodal dissection in patients with differentiated thyroid cancer and lateral metastases between the anterior and posterior approaches to the sternocleidomastoid muscle (SCM)

NCT ID: NCT06146231 Recruiting - Breast Cancer Clinical Trials

Motiva Flora® Aesthetic Breast Recon® Clinical Study

Start date: August 18, 2023
Phase: N/A
Study type: Interventional

The present study will be based on a hybrid breast reconstruction approach with initial skin expansion using the Motiva Flora® Tissue Expander followed by a serial fat grafting session and a final step that includes the placement of a permanent breast implant Ergonomix2®.

NCT ID: NCT06136559 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Start date: December 13, 2023
Phase: Phase 3
Study type: Interventional

The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior therapy. The primary hypotheses are that (1) nemtabrutinib is non-inferior to ibrutinib or acalabrutinib with respect to objective response rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 by blinded independent central review (BICR) and (2) nemtabrutinib is superior to ibrutinib or acalabrutinib with respect to progression free survival (PFS) per iwCLL Criteria 2018 by BICR.

NCT ID: NCT06124183 Completed - Clinical trials for Mental Health Wellness 1

Emotional Intelligence Program for Adolescents With Antisocial Behavior (DYNAMIS)

DYNAMIS
Start date: January 11, 2022
Phase: N/A
Study type: Interventional

This study assessed the effectiveness of an emotional intelligence program based on the Salovey and Mayer model among adolescents exhibiting antisocial behavior. A quasi-experimental design was employed, involving 231 Colombian adolescent offenders (122 in the experimental group). A 12-session psychological protocol was implemented. The primary question it aims to address is whether it is feasible for adolescents with antisocial behavior to reduce negative emotional symptoms related to mental health, such as anxiety, stress, and depression, while simultaneously improving their emotional skills. It was observed that those who completed the program showed significant improvements in emotional intelligence, emotional balance, and resilience while experiencing a decrease in emotional symptoms, particularly in stress.

NCT ID: NCT06118775 Not yet recruiting - Septic Shock Clinical Trials

Evaluating Dynamic Arterial Elastance in Septic Shock Patients.

EaDyn
Start date: July 1, 2024
Phase: N/A
Study type: Interventional

Assess the effectiveness and safety of using dynamic arterial elastance as a tool for weaning vasopressor support in patients with septic shock, compared to a control group

NCT ID: NCT06117891 Recruiting - Clinical trials for Unresectable Hepatocellular Carcinoma

An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery

REFINE-IO
Start date: November 27, 2023
Phase:
Study type: Observational

This is an observational study in which only data will be collected from adults with unresectable hepatocellular carcinoma. These adults should be prescribed a different treatment after treatment with atezolizumab and bevacizumab, or another similar combination of drugs, by their doctors. Unresectable hepatocellular carcinoma (uHCC) is a type of liver cancer that cannot be treated with surgery. In the past, sorafenib was the only approved first-line anti-cancer drug for people with uHCC. Regorafenib and other drugs were approved as second-line treatments for uHCC if a person could not take sorafenib or it stopped working for them. Lately, another first-line (1L) treatment called immuno-oncology (IO) immune checkpoint inhibitor combination (1L-IO combo), like atezolizumab with bevacizumab (AB), has become the preferred choice of treatment. This is because of the meaningful impact on patient survival. 1L-IO combo are drugs that help the body's defense system recognize and kill cancer cells. Since the other treatments were previously approved for use following sorafenib, the best order to take these treatments in following an 1L-IO combo is unknown. To better understand and determine this order, more knowledge is needed about how well different treatments work in participants with uHCC who have been treated with AB or another 1L-IO combo. The main purpose of this study is to learn more about how well different treatments work when given after first-line treatment with AB or another approved 1L-IO combo. To do this, researchers will collect data on how long the participants live (also called overall survival) from the start of any treatment given after the first-line treatment. In addition, researchers will also collect the following information to learn more about the participants who will be given a different treatment after the 1L-IO combo: - characteristics including age, sex, and race, and signs and symptoms of the participants over the duration of their first-line treatment - the length of time from the first to the last dose (also called duration of therapy) of the treatments given after the 1L-IO combo - the length of time until a participant's cancer worsens, or they die (also called progression free survival) from the start of the treatments given after the 1L-IO combo - the number of participants whose tumor completely disappears or shrinks (also called overall tumor response) after taking the treatments given after the 1L-IO combo - the sequence of treatments given after the 1L-IO combo Data will be collected from September 2023 to December 2026 and cover a period of around 3 years. The data will be collected using medical records or by interviewing the participants during their routine visits to the doctor. Researchers will observe participants from the start of the treatment given after the 1L-IO combo until the end of their participation in the study. In this study, only data from routine care will be collected. No visits or tests are required as part of this study.

NCT ID: NCT06111144 Enrolling by invitation - Healthy Volunteers Clinical Trials

Effects of Polarized and Pyramidal Training Combined With or Without Mindfulness in Amateur Runners

Start date: August 16, 2023
Phase: N/A
Study type: Interventional

Road running in athletics has grown worldwide in recent years, which has led to an increase in the number of recreational runners. Despite this growth, research addressing this population is scarce, with major limitations and methodological weaknesses. Two of the topics of recent interest in runners are the effects of training intensity distribution (TID) and mental training using mindfulness on running time, body composition and physiological parameters related to performance in endurance sports; the maximal oxygen consumption (VO2max), maximal aerobic speed (MAS) and ventilatory thresholds (VT). The scarce evidence found identifies the TID polarized model as the most effective in sports performance and TID pyramidal model as the most used by elite runners. For mindfulness, it is identified as an emerging program that could contribute to performance in endurance sports.

NCT ID: NCT06092294 Completed - Clinical trials for Decision Making in Soccer Players and Executive Functions

Numerical Superiority and Inferiority Compared With Conventional Training on PTK and Executive Functions in Soccer

Start date: July 3, 2023
Phase: N/A
Study type: Interventional

There is a great need to establish reliable evaluation and intervention protocols to improve the tactical component, decision making (DM) and procedural tactical knowledge (PTK) in soccer. Objectives: to determine the effects of a 12-week follow up numerical superiority and numerical inferiority tactical training program on PTK, which will be evaluated by calculating offensive, defensive and global effectiveness indexes (EI) of 24 amateur male soccer players, as well as the effect on their executive functions. Method: randomized controlled trial, with two groups in parallel, experimental group (EG) and control group (CG), with different measurements over time (pretest, intermediate test 1, intermediate test 2 and posttest).

NCT ID: NCT06086080 Recruiting - Clinical trials for Patellar Dislocation

Non-operative Treatment in First-time Patellar Dislocation

Start date: October 2, 2023
Phase: N/A
Study type: Interventional

Study to evaluate the conservative treatment of patients after their first episode of primary lateral patellar dislocation. Randomized controlled trial with 2 groups: standard treatment (2-weeks with brace) followed by physical therapy, compared with knee taping and physical therapy. 1-year follow-up. Measurements include physical exam, radiographs and MRI. Outcomes: recurrence, lateral patellar tilt, functional scores, apprehension, pain. Hypothesis: less recurrence in the knee taping group, as well as better functional scores.

NCT ID: NCT06065748 Recruiting - Clinical trials for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Start date: December 11, 2023
Phase: Phase 3
Study type: Interventional

This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy.